



Figure S1. Greater PTS Activity and Increased Sensitivity to AP in *BRAF^{V600E}* Human Melanoma Cells Compared to *BRAF^{WT}* Cells. (A) *BRAF^{V600E}* WM983B melanoma cells and *BRAF^{WT}* WM3743 melanoma cells were cultured with and without 1 mM DFMO for 40 h and then pulsed with 0.5 μM ³H-spermidine for 60 minutes at 37°C. Cells were washed with cold PBS containing 50 μM spermidine, and cell lysates were assayed for CPM ³H-spermidine per mg protein by scintillation counting. (B) WM983B and WM3743 melanoma cells were treated with increasing doses of AP. After 72 h of culture, cell survival was determined via EZQuant™ Cell Quantifying assay. IC50 values were calculated by GraphPad Prism 6. (C) WM983B melanoma cells were treated with increasing doses of AP with or without 1 mM DFMO. After 72 h of culture, cell survival was determined via EZQuant™ Cell Quantifying assay. 72 h IC50 values were calculated by GraphPad Prism 6. Values are the mean of 5-6 samples ± SD.